Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Published:2013-11 Issue: Volume: Page:
ISSN:
Container-title:Therapeutic Agents: Small Molecule Kinase Inhibitors
language:
Short-container-title:

Author:

Kim Sunkyu,Loo Alice,Chopra Rajiv,Caponigro Giordano,Huang Alan,Vora Sadhna,Parasuraman Sudha,Howard Steve,Keen Nicholas,Sellers William,Brain Christopher

Publisher

American Association for Cancer Research

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK Inhibitors and FDA: Approved and Orphan;Cancers;2024-04-19

2. Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine;Interdisciplinary Cancer Research;2024

3. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma;Journal of Investigative Dermatology;2023-01

4. CDK inhibitors from past to present: A new wave of cancer therapy;Seminars in Cancer Biology;2023-01

5. Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers;Therapeutic potential of Cell Cycle Kinases in Breast Cancer;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP